Home Monitoring with traffic light is launched globally

442

The new Biotronik Home Monitoring is now industry’s first online platform integrating an intelligent traffic light system that simplifies remote monitoring of patients with the company’s implantable cardiac devices (ICD), allowing early detection of clinically relevant events and assured patient care.

Using an intuitive, red-yellow-coded traffic light concept, Biotronik Home Monitoring quickly and easily identifies patients with the most clinically relevant events or changes in device status, enabling physicians to focus on the patients who require attention and thereby, preventing further worsening in patients’ condition.


The unique CardioMessenger patient device gives patients freedom to be completely mobile while wirelessly transmitting, via the cellular network, important clinical and device status information to the Home Monitoring secure website for physician evaluation.


The system provides physicians with a daily updated and consolidated online patient status summary, also called CardioReport. This report can be accessed at any time and from any computer via the Internet. The comprehensive clinical information includes atrial and ventricular arrhythmia and heart failure diagnostics, intracardiac electrograms, IEGM-Online HD, and device performance data. This status summary on the Biotronik Home Monitoring secure website enables physicians to quickly review the most important information at a glance.


The multiple user access to the new system facilitates the establishment of collaborative care networks, allowing multiple clinics and physicians to simultaneously manage an individual patient to form what is essentially a “virtual clinic”.


TRUST (Lumax-T/Lumos-T safely reduces routine office device follow-up), the first and largest clinical trial of its kind, results have clinically proven that Biotronik Home Monitoring is as safe as conventional in-office follow-ups. This multicentre, prospective, randomised trial of 1,443 ICD patients at 105 different sites across the USA and Canada has demonstrated that Biotronik Home Monitoring significantly reduces the number of in-office follow-up visits by 43%, while maintaining patient safety.


The TRUST trial has also shown that with the Biotronik system the time from onset of a patient’s arrhythmic event to evaluation was significantly reduced by up to 35 days, depending on the type of arrhythmia detected.


The new patient management system extends the flexibility of the system’s worldwide remote monitoring capabilities, providing an efficient and convenient solution to improve patient care and optimize resources in today’s busy cardiac clinics.

(Visited 49 times, 1 visits today)